Sign Out
Metastatic breast cancer
Adult: In patients with unresectable, locally recurrent cases who have relapsed following adjuvant/neoadjuvant chemotherapy: In combination with paclitaxel: 1,250 mg/m2 via infusion over 30 minutes on Days 1 and 8 of a 21-day cycle. Dose may be reduced with each cycle or within a cycle based on toxicity. Patients should have an absolute granulocyte count of at least 1,500 x 106/L and platelet count of 100,000 x 106/L prior to initiation of therapy.
Intravenous
Locally advanced bladder cancer, Metastatic bladder cancer
Adult: In combination with cisplatin: 1,000 mg/m2 via infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle, followed by a 1-week rest period. This 4-week cycle is then repeated. Dose may be reduced with each cycle or within a cycle based on the amount of toxicity. Patients should have an absolute granulocyte count of at least 1,500 x 106/L and platelet count of 100,000 x 106/L prior to initiation of therapy. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines).
Intravenous
Locally advanced ovarian cancer, Metastatic ovarian cancer
Adult: In cases that have relapsed at least 6 months after completion of platinum-based therapy: In combination with carboplatin: 1,000 mg/m2 via infusion over 30 minutes on Days 1 and 8 of each 21-day cycle. Dose may be reduced with each cycle or within a cycle based on toxicity. Patients should have an absolute granulocyte count of at least 1,500 x 106/L and platelet count of 100,000 x 106/L prior to initiation of therapy.
Intravenous
Locally advanced non-small cell lung carcinoma, Metastatic non-small cell lung carcinoma
Adult: As monotherapy: 1,000 mg/m2 once weekly via infusion over 30 minutes for 3 weeks followed by a 1-week rest period. This 4-week cycle is then repeated. In combination with cisplatin: 1,250 mg/m2 via infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, followed by a 1-week rest period. This 3-week cycle is then repeated. Alternatively, 1,000 mg/m2 via infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle, followed by a 1-week rest period. This 4-week cycle is then repeated. Dose may be reduced with each cycle or within a cycle based on toxicity. Patients should have an absolute granulocyte count of at least 1,500 x 106/L and platelet count of 100,000 x 106/L prior to initiation of therapy.
Intravenous
Locally advanced adenocarcinoma of pancreas, Metastatic adenocarcinoma of pancreas
Adult: 1,000 mg/m2 once weekly via infusion over 30 minutes for 7 weeks, followed by a 1-week rest period. Subsequent cycles: 1,000 mg/m2 once weekly for 3 consecutive weeks out of every 4 weeks. Alternatively, 1,000 mg/m2 on Days 1, 8, and 15 of each 28-day cycle. Dose may be reduced with each cycle or within a cycle based on toxicity. Patients should have an absolute granulocyte count of at least 1,500 x 106/L and platelet count of 100,000 x 106/L prior to initiation of therapy. Treatment recommendations may vary among countries (refer to specific local guidelines).
